Metsera, a clinical-stage biotechnology startup that develops drugs for obesity and metabolic diseases, launched on Thursday with what it described as a “broad portfolio” of weight-loss treatments that it hopes to bring to market. The company, which has already acquired the U.K.-based startup, Zihipp, and formed a licensing pact with a South Korean drugmaker, D&D Pharmatech, claims that its products could eventually compete with industry leaders Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro.... Read this story
